Search Result

Results for "

CNS disease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Amyloid-β (2) Apoptosis (3) Beta-secretase (2) c-Fms (1) Calcium Channel (3) Caspase (3) Cholinesterase (ChE) (2) COX (1) Dopamine Receptor (3) Drug Metabolite (2) DYRK (2) Endogenous Metabolite (3) Epigenetic Reader Domain (1) Eukaryotic Initiation Factor (eIF) (1) FKBP (1) GSK-3 (1) HDAC (3) HIV (1) iGluR (3) Integrin (2) Interleukin Related (1) LRRK2 (1) mAChR (1) MAP3K (1) mGluR (4) Monoamine Oxidase (1) mTOR (2) nAChR (1) NO Synthase (1) NOD-like Receptor (NLR) (1) Opioid Receptor (2) P2X Receptor (2) Potassium Channel (1) Raf (1) Small Interfering RNA (siRNA) (1) Sodium Channel (1) Somatostatin Receptor (2) Tau Protein (1) Vasopressin Receptor (1) VEGFR (1) γ-secretase (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (7) Neurological Disease (57)

By Targets:

5-HT Receptor (4)

Amyloid-β (2)

Apoptosis (3)

Beta-secretase (2)

c-Fms (1)

Calcium Channel (3)

Caspase (3)

Cholinesterase (ChE) (2)

COX (1)

Dopamine Receptor (3)

Drug Metabolite (2)

DYRK (2)

Endogenous Metabolite (3)

Epigenetic Reader Domain (1)

Eukaryotic Initiation Factor (eIF) (1)

FKBP (1)

GSK-3 (1)

HDAC (3)

HIV (1)

iGluR (3)

Integrin (2)

Interleukin Related (1)

LRRK2 (1)

mAChR (1)

MAP3K (1)

mGluR (4)

Monoamine Oxidase (1)

mTOR (2)

nAChR (1)

NO Synthase (1)

NOD-like Receptor (NLR) (1)

Opioid Receptor (2)

P2X Receptor (2)

Potassium Channel (1)

Raf (1)

Small Interfering RNA (siRNA) (1)

Sodium Channel (1)

Somatostatin Receptor (2)

Tau Protein (1)

Vasopressin Receptor (1)

VEGFR (1)

γ-secretase (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (2)

Infection (2)

Inflammation/Immunology (7)

Neurological Disease (57)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-144764

5-HT1A antagonist 1	5-HT Receptor	Neurological Disease
5-HT1A antagonist 1 (compound 6f) is a potent and selective antagonist of 5-HT_1A receptor, with a K_i of 35 nM. 5-HT1A antagonist 1 can be used for the research of CNS diseases .

HY-146068

AEP-IN-1	Others	Neurological Disease
AEP-IN-1 (Compound 13e) is a CNS agent-like non-covalent inhibitor of asparagine endopeptidase (AEP), with the IC₅₀ of 89 nM. AEP-IN-1 can be used for the research of numerous neurological diseases such as Alzheimer’s disease (AD) .

HY-154957

mTOR inhibitor-11	mTOR	Neurological Disease
mTOR inhibitor-11 (Compound 9) is a brain-penetrant mTOR inhibitor (IC₅₀: 21 nM for pS6). mTOR inhibitor-11 also inhibits pCHK1 and PDE4D with IC₅₀s of 17.2 and 17.0 μM. mTOR inhibitor-11 can be used for research of CNS disease .

HY-154958

mTOR inhibitor-12	mTOR	Neurological Disease
mTOR inhibitor-12 (Compound 11) is a selective brain penetrant mTOR inhibitor without genotoxicity risk. mTOR inhibitor-12 can be used for the research of CNS diseases .

HY-111263

NIAD-4	Amyloid-β	Neurological Disease
NIAD-4 is a fluorophore for optical imaging of amyloid-β (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (K_i) of 10 nM .

HY-156438

NT-0796	NOD-like Receptor (NLR)	Neurological Disease
NT-0796 is a selective and CNS-penetrant NLRP3 inflammasome inhibitor with an IC₅₀ of 0.32 nM in PBMC assay. NT-0796 is an isopropyl ester that undergoes intracellular conversion to NDT-19795, the carboxylic acid active species. NT-0796 has the potential for neuroinflammatory diseases research .

HY-18679

TC-N 22A	mGluR	Neurological Disease
TC-N 22A is a potent, selective, orally active and brain-permeable mGlu₄ PAM with an EC₅₀ of 9 nM in human mGlu₄-expressing BHK cells. TC-N 22A is less active (EC₅₀>10 μM) in agonist and PAM model at mGlu 1, 2, 3, 5, and 7 receptors. TC-N 22A has the potential for research of CNS disease in vivo .

HY-150503

KH-259	HDAC	Neurological Disease
KH-259 (compound 1) is a potent, selective and CNS-penetrant HDAC6 inhibitor, with an IC₅₀ of 0.26 μM. KH-259 has antidepressant effects in mice through the inhibition of HDAC6 in the brain. KH-259 can be used for neurodegenerative diseases research .

HY-116016

Etilevodopa L-DOPA ethyl ester; Levodopa ethyl ester	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-116016A

Etilevodopa hydrochloride L-DOPA ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-144074

LRRK2-IN-4	LRRK2	Neurological Disease
LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC₅₀ of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease .

HY-156585

CNS-11

Tau Protein Neurological Disease

CNS-11 is a compoud that disaggregates tau fibrils. CNS-11 can be used for Alzheimer's disease (AD) research .

CNS-11	Tau Protein	Neurological Disease
CNS-11 is a compoud that disaggregates tau fibrils. CNS-11 can be used for Alzheimer's disease (AD) research .

HY-W001601

Budipine	iGluR	Neurological Disease
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .

HY-10035

TTA-P2 T-Type calcium channel inhibitor	Calcium Channel	Neurological Disease
TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease .

HY-10035A

(R)-TTA-P2	Others	Neurological Disease
(R)-TTA-P2 is the isomer of TTA-P2 (HY-10035), and can be used as an experimental control. TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease .

HY-50707

(Rac)-TTA-P2 (Rac)-T-Type calcium channel inhibitor	Others	Neurological Disease
(Rac)-TTA-P2 is the isomer of TTA-P2 (HY-10035), and can be used as an experimental control. TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease .

HY-115726

FRM-024

γ-secretase Neurological Disease

FRM-024 is a potent CNS-penetrant gamma secretase modulator for familial Alzheimer’s disease.
HY-156986

ITH15004

P2X Receptor Neurological Disease

ITH15004 is a CNS-penetrated P2X7 antagonist, used for the study of neurodegenerative diseases .
HY-W019710

(E,E)-RGFP966

HDAC Neurological Disease

(E,E)-RGFP966 is a selective and CNS permeable HDAC3 inhibitor that can be used for the research of Huntington’s disease .

FRM-024	γ-secretase	Neurological Disease
FRM-024 is a potent CNS-penetrant gamma secretase modulator for familial Alzheimer’s disease.

ITH15004	P2X Receptor	Neurological Disease
ITH15004 is a CNS-penetrated P2X7 antagonist, used for the study of neurodegenerative diseases .

(E,E)-RGFP966	HDAC	Neurological Disease
(E,E)-RGFP966 is a selective and CNS permeable HDAC3 inhibitor that can be used for the research of Huntington’s disease .

HY-109055

Elenbecestat E2609	Beta-secretase	Neurological Disease
Elenbecestat (E2609) is a potent, orally bioavailable and CNS-penetrant BACE-1 inhibitor. Elenbecestat has the potential for Alzheimer's disease (AD) research .

HY-132981

Lu AF27139	P2X Receptor	Neurological Disease
Lu AF27139 is a potent, selective, and orally active antagonist of P2X7 receptor (IC₅₀s of 12 and 2.4 nM for human and rat, K_is of 22, 54, and 13 nM for mouse, human, and rat, respectively). Lu AF27139 has rodent-active and CNS-penetrant character. Lu AF27139 has the potential for the research of CNS diseases .

HY-119943

PF-06256142	Dopamine Receptor	Neurological Disease
PF-06256142 is a potent, selective, CNS-penetrant and orally active agonist of the D1 receptor, with an EC₅₀ and K_i of 33 nM and 12 nM, respectively. PF-06256142 has the potential for the research of schizophrenia and Parkinson's disease .

HY-160446

BET-IN-24	Epigenetic Reader Domain	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Bet-in-24 (example 2) is a bromodomain and extra-terminal (BET) inhibitor. BET-IN-24 can be used in the study of virology, heart failure, inflammation, central nervous system (CNS) diseases and many cancers

HY-161084

CSF1R-IN-18	c-Fms	Neurological Disease Cancer
CSF1R-IN-18 (Compdound 16t), para-aniline derivative, is a colony-stimulating factor 1 receptor (CSF1R) inhibitor. CSF1R-IN-18 can be used for the research of cancers, CNS-diseases and bone diseases .

HY-109527

5-HT7 agonist 1	5-HT Receptor	Neurological Disease
5-HT7 agonist 1 is a selective 5-HT7 receptor agonist, with an IC₅₀ of 222.93 nM, can be used for the 5-HT7 receptor related disease, such as CNS disorders.

HY-149243

BChE-IN-16	Cholinesterase (ChE)	Neurological Disease
BChE-IN-16 (compound 87) is a highly potent BChE inhibitor with an IC₅₀ of 3.8 nM for hBChE. BChE-IN-16 has low cytotoxicity, potential CNS permeability, unique adaptability and can be used in Alzheimer's disease (AD) research.

HY-162232

mGluR2 agonist 1	mGluR	Neurological Disease
mGluR2 agonist 1 (Compound 5b) is a potent and selective metabotropic glutamate 2 receptor (mGluR) agonist with an EC₅₀ of 82 nM. mGluR2 agonist 1 can be used for the research of central nervous system (CNS) diseases .

HY-145778

AGI-41998	Somatostatin Receptor	Neurological Disease
AGI-41998 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-41998 is a brain-penetrant compound. AGI-41998 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease .

HY-145777

AGI-43192	Somatostatin Receptor	Neurological Disease Cancer
AGI-43192 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-43192 is a potent, but limited brain-penetrant compound. AGI-43192 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease .

HY-113616A

VU0364572 TFA	mAChR	Neurological Disease
VU0364572 TFA is an orally active and selective allosteric agonist of the M1 muscarinic receptor with an EC₅₀ of 0.11 μM. VU0364572 TFA has neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer’s Disease. VU0364572 TFA is CNS penetrant .

HY-144696

Dyrk1A/α-synuclein-IN-2	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual Dyrk1A and α-synuclein aggregation inhibitor with an IC₅₀ of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect .

HY-155058

Nav1.3 channel inhibitor 1	Sodium Channel	Neurological Disease
Nav1.3 channel inhibitor 1 (compound 15b) is a state-dependent voltage-gated sodium channel Na_v1.3 inhibitor (IC₅₀=20 nM). Nav1.3 channel inhibitor 1 can penetrate the blood-brain barrier and can be used in the research of nervous system diseases .

HY-Y0966

Glycine 4 Publications Verification	Endogenous Metabolite iGluR VEGFR Small Interfering RNA (siRNA)	Neurological Disease
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

HY-P1333

Dynorphin A	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-122647

Valiglurax VU0652957; VU2957	mGluR	Neurological Disease
Valiglurax (VU0652957) is a potent, orally active and selective mGlu4 positive allosteric modulator with EC₅₀ values of 64.6 nM and 197 nM for hmGlu₄/Gqi5 and rmGlu₄ GIRK, respectively. Valiglurax is a central nervous system (CNS) penetrant. Valiglurax can be used in research of Parkinson's disease .

HY-14418

VU0361737 ML-128	mGluR	Neurological Disease
VU0361737 (ML-128) is a potent, selective and CNS penetrant positive allosteric modulator of metabotropic glutamate receptor 4 (mGluR₄ PAM), with EC₅₀s of 240 nM and 110 nM for human and rat mGluR₄ receptors, respectively. VU0361737 has neuroprotective effect. VU0361737 is potential for Parkinson's disease research .

HY-12150

CCMI AVL-3288; UCI-4083	nAChR	Neurological Disease
CCMI (AVL-3288) is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs. CCMI has potential in CNS diseases with cognitive dysfunction .

HY-P1333A

Dynorphin A TFA	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A TFA is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A TFA is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A TFA can induce neuronal death, and can be used in the research of neurological disease .

HY-144695

Dyrk1A/α-synuclein-IN-1	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual Dyrk1A and α-synuclein aggregation inhibitor with IC₅₀ values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect .

HY-114331

DLK-IN-1	MAP3K	Neurological Disease
DLK-IN-1 is a selective, orally active inhibitor of dual leucine zipper kinase (DLK, MAP3K12), with a K_i of 3 nM. DLK-IN-1 retains excellent CNS penetration and is well tolerated following multiple days of dosing at concentrations that exceed those required for DLK inhibition in the brain. DLK-IN-1 has activity in a model of Alzheimer’s Disease.

HY-161331

S16–1029	Cholinesterase (ChE)	Neurological Disease
S16–1029 is a selective and orally active butyrylcholinesterase (BChE) inhibitor with IC₅₀s of 11.35 nM and 48.1 nM for eqBChE and hBChE, respectively. S16–1029 could cross the blood-brain barrier (BBB) and reach the central nervous system (CNS). S16–1029 can be used for Alzheimer's disease (AD) research .

HY-115498

ARN14494	Apoptosis NO Synthase Interleukin Related COX	Neurological Disease Inflammation/Immunology
ARN14494 is a potent and selective serine palmitoyltransferase (SPT) inhibitor, with an IC₅₀ of 27.3 nM. ARN14494 affects the CNS in terms of anti-inflammation and neuroprotection. ARN14494 protects neurons from β-amyloid 1-42-induced neurotoxicity through a variety of mechanisms, including anti-oxidation, anti-apoptosis, and anti-inflammation. ARN14494 can be used for Alzheimer’s disease research .

HY-108831

Natalizumab 1 Publications Verification	Integrin	Inflammation/Immunology
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-147405

Tinlorafenib PF-07284890; ARRY-461	Raf	Cancer
Tinlorafenib (PF-07284890) (compound 10) is an orally active BRAF kinase inhibitor, with IC₅₀s of 4.25 and 2.7 nM for BRAF ^V600E/V600K respectively. Tinlorafenib demonstrates CNS penetration and can be used in the research of BRAF-associated malignant and benign tumors of the CNS as well as extracranial malignancies .

HY-108831A

Natalizumab (Solution) 1 Publications Verification	Integrin	Inflammation/Immunology
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-149555

DNL343	Eukaryotic Initiation Factor (eIF)	Neurological Disease
DNL343 is a brain-penetrating activator of eukaryotic initiation factor 2B (eIF2B) that inhibits the abnormal integrated stress response (ISR). DNL343 inhibits ISR activity in the central nervous system (CNS) and reverses neurodegeneration and neuroinflammation. DNL343 also prevents motor dysfunction and premature death in eIF2B loss-of-function (LOF) mutant mice. DNL343 has inhibitory potential in studies of vanishing white matter disease (VWMD) driven by eIF2B LOF and chronic ISR activation .

HY-130795

GSK-3β inhibitor 2 1 Publications Verification	GSK-3	Neurological Disease
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active GSK-3β inhibitor with an IC₅₀ of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease .

HY-124619

GPI-1046	FKBP HIV	Infection Neurological Disease
GPI-1046 is a immunophilin ligand without antibiotic action and attenuates ethanol intake in part through the upregulation of glutamate transporter 1 (GLT1) in PFC and NAc-core. GPI-1046 is an analog of FK506, which is an immunophilin ligand that has been shown neuroprotective effects in neurodegenerative disease models . GPI-1046 readily crosses the blood-brain barrier and promotes the regeneration of dopamine (DA) cells in the CNS in association with functional recovery in rodent models . GPI-1046 improves HIV-associated injury of peripheral nerves .

HY-131068

BACE-1 inhibitor 2

Beta-secretase Neurological Disease

BACE-1 inhibitor 2 is a potent and CNS permeable BACE-1 inhibitor with an IC₅₀ of 1.5 nM in BACE-1 enzymatic assay .

HY-145845

HDAC1/MAO-B-IN-1	HDAC Monoamine Oxidase	Neurological Disease
HDAC1/MAO-B-IN-1 is a potent, selective and cross the blood-brain barrier HDAC1/MAO-B inhibitor with IC₅₀ values of 21.4 nM and 99.0 nM for HDAC1 and MAO-B, respectively. HDAC1/MAO-B-IN-1 has the potential for the research of Alzheimer’s disease .

Cat. No.	Product Name

HY-L028

CNS-Penetrant Compound Library

856 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 856 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L013

Neuronal Signaling Compound Library

2542 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 2542 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

HY-L070

Neuroprotective Compound Library

1058 compounds

Neurodegenerative diseases are characterised by progressive dysfunction and death of neurons, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). Neuroprotection is an approach to preserve neurons so that neurons cannot be hurt by different pathological factors in neurodegenerative diseases. Neuroprotectors are some agonists and antagonists targeting some key targets in neuroprotactive signal pathways, such as calcium and sodium channel blockers, GABA receptor agonists, NMDA receptor Antagonists, etc. Current neuroprotectors cannot reverse existing damage, but they may protect against further nerve damage and slow down any degeneration of the central nervous system (CNS) and still play important roles in the treatment of neurodegenerative diseases.

MCE offers a unique collection of 1058 compounds with potential neuroprotective activities. These compounds mainly act on some key targets in neuroprotetive signal pathways, such as calcium channel, sodium channel, adenosine A1 receptor, etc. MCE Neuroprotective Compopund Library is a useful tool in neuroprotective drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P1333

Dynorphin A	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-P1240

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat 4 Publications Verification MOG (35-55)	Peptides	Neurological Disease Inflammation/Immunology
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination .

HY-P1240B

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate 4 Publications Verification MOG (35-55) (acetate)	Peptides	Neurological Disease Inflammation/Immunology
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) acetate is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate produces a relapsing-remitting neurological disease with extensive plaque-like demyelination .

HY-P5462

PLP (180-199)	Peptides	Others
PLP (180-199) is a biological active peptide. (This is amino acids 180-199 fragment of myelin proteolipid protein (PLP). PLP, the most abundant myelin protein of the central nervous system, has been used in multiple sclerosis (MS) studies. MS is a chronic inflammatory demyelinating disease of the CNS.)

HY-P1333A

Dynorphin A TFA	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A TFA is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A TFA is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A TFA can induce neuronal death, and can be used in the research of neurological disease .

HY-P1240A

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA 4 Publications Verification MOG (35-55) (TFA)	Peptides	Neurological Disease Inflammation/Immunology
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) TFA is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA produces a relapsing-remitting neurological disease with extensive plaque-like demyelination .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks